Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00985517 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
A Phase 1 study of Idiopathic Parkinson´s Disease, sponsored by Sangamo Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 11
- Study locations
NCT00985517: Completed Phase 1 study of Idiopathic Parkinson´s Disease, sponsored by Sangamo Therapeutics.
NCT00985517 is a Phase 1 study of Idiopathic Parkinson´s Disease that has completed, run by Sangamo Therapeutics. The registered enrollment target is 57 participants, below the 212-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (73% lower). The trial reports 11 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00985517, a Phase 1 study of Idiopathic Parkinson´s Disease, has completed, sponsored by Sangamo Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 11
- Study locations
Study Summary
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
Primary Outcome
Number of Participants who received CERE-120 Treatment
Conditions Studied
Interventions
- BIOLOGICAL CERE-120: Adeno-Associated Virus Delivery of Neurturin
- PROCEDURE Sham Surgery
Study Locations (11)
New York
- Beth Israel Medical Center - New York
- Columbia University Medical Center - New York
- Mount Sinai Medical Center - New York
California
- Stanford School of Medicine - Palo Alto
- University of California, San Francisco - San Francisco
Alabama
- University of Alabama at Birmingham - Birmingham
Georgia
- Emory University - Atlanta
Illinois
- Rush University Medical Center - Chicago
North Carolina
- Duke University - Durham
Pennsylvania
- University of Pennsylvania - Philadelphia
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2009-10-29 |
| Est. Completion | 2017-11-16 |
| Phase | Phase 1 |
What the finished NCT00985517 record still lists
NCT00985517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, below the 212-participant average among 7 other Idiopathic Parkinson´s Disease trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Idiopathic Parkinson´s Disease appearing as the primary indexed condition, and to 2 interventions - of which CERE-120: Adeno-Associated Virus Delivery of Neurturin is the first listed.
NCT00985517 lists 11 locations in 8 states (New York, California, Alabama).
Frequently Asked Questions
What is clinical trial NCT00985517 about?
NCT00985517 is a clinical study titled "Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease". The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
What is the current status of trial NCT00985517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2009-10-29. Estimated completion is 2017-11-16.
What conditions does trial NCT00985517 study?
This clinical trial studies the following conditions: Idiopathic Parkinson´s Disease.
What interventions are being tested in trial NCT00985517?
The interventions under investigation include: CERE-120: Adeno-Associated Virus Delivery of Neurturin (BIOLOGICAL), Sham Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT00985517?
This trial is sponsored by Sangamo Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00985517 being conducted?
This trial has 11 study locations across Alabama, California, Georgia, Illinois, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Parkinson´s Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease
RECRUITING · Phase 1
-
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
COMPLETED · Phase 1
-
Infusion of Apomorphine: Long-term Safety Study
ACTIVE NOT RECRUITING · Phase 3
-
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
COMPLETED · Phase 3
-
Long Term Study of Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
COMPLETED · Phase 3
-
Efficacy and Safety Study of Inhaled CVT 301 in Parkinson's Disease Patients for Treatment of OFF Episodes
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI